This Is MS Multiple Sclerosis Community: Knowledge & Support

Accentia biopharmaceuticals announces strategic agreement with Baxter



Accentia Biopharmaceuticals, Inc. today announced a strategic agreement with Baxter Healthcare Corporation to provide Accentia with the exclusive, worldwide right to purchase Baxter's cyclophosphamide, which is marketed under the brand name Cytoxan(R), for the treatment of designated autoimmune diseases including multiple sclerosis.

Cyclophosphamide is the active drug used in Revimmune(TM) therapy, Accentia's proprietary system-of-care being developed for the treatment of a broad range of autoimmune diseases.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2018

_________________
The Multiple Sclerosis Resource Centre

Squiffy's House of Fun - Laughter for Multiple Sclerosis

How is this going to effect the availability of Cyclophosphamide? It is widely used for other indications e.g. cancer, immuno-ablation in ASCT, autoimmune diseases, even in MS it has already been used for a long time in a way compareable to Mitoxantrone. Will Cyclophosphamide be now only obtaineable through Accentia?
Arent there any generic versions of CTX on the market?

The original patent has long expired - will Accentia be able to get a new patent for a new indication (i.e. high dose CTX in MS)?
Is it generally possible to get new patents for an established Durg each and every time onecan prove efficacy for a new indication?

--Frank

_________________
Treatment: CCSVI both IJV ballooned 09/2010, No DMDs, Tysabri on hold after 24 Infusions, after LDN, ABX Wheldon Regime for 1 year.